Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.69 |
| ▸ | CD69 | Q07108 | 10/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766356 | 1.00 | BTK (0.69) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL20683070 | 0.91 | BTK (0.72) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29766421 | 0.91 | BTK (0.72) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL20533214 | 0.88 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL20533212 | 0.88 | BTK (0.70) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29766298 | 0.87 | BTK (0.75) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16814092 | 0.87 | BTK (0.75) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL20683069 | 0.87 | BTK (0.75) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL16814044 | 0.86 | BTK (0.53) | BTKCD69CYP2C9CYP3A4 | |
| SCHEMBL29918695 | 0.86 | BTK (0.53) | BTKCD69CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885CD69 4146/4885CYP2C9 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.